Other inflammatory mediators including tumour necrosis factor (TNF) and IL-13 also have a negative impact on gut barrier integrity by decreasing the expression of claudin proteins (Prasad et al
CNET and Yahoo may earn commission from links in this article.
Clinical anecdotes that patients treated with semaglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist approved for treating type 2 diabetes (T2D) in 2017 and for weight management in 2021 reported reduced desire to drink and smoke have attracted attention regarding its potential to treat addiction [12]
Common side effects, including nausea, constipation, and reflux, may lead some to stop treatment altogether
Compliance Notice: For controlled, non-clinical laboratory research only
Some people notice reduced bloating and a slight shift in how clothes fit around the midsection